<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00927407</url>
  </required_header>
  <id_info>
    <org_study_id>MALG-0603</org_study_id>
    <nct_id>NCT00927407</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Malathion Gel 0.5% and Malathion 0.5% Lotion (Ovide) in Patients With Head Lice</brief_title>
  <official_title>A Randomized, Single-Dose, Parallel Group, Comparative Pharmacokinetic (PK) Study to Evaluate Malathion Gel 0.5% Versus Ovide (Malathion) Lotion 0.5% in Patients With Pediculosis Capitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taro Pharmaceuticals USA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taro Pharmaceuticals USA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, 24 adult patients with head lice will be treated with a topical malathion head
      lice treatment; 12 patients will be treated with a novel product, Malathion Gel, 0.5%, and
      other 12 patients will be treated with Ovide Lotion 0.5% marketed by Taro Pharmaceuticals
      USA, Inc. The primary objective of this study is to compare the blood level exposure of
      Malathion 0.5% Gel to that of the OVIDE Lotion 0.5%.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, single-dose, parallel group, comparative PK study. Patients will be randomly
      assigned in 1:1 ratio to the study products. Twenty four (24) consenting patients, age 18
      years and older, who meet Inclusion/Exclusion criteria will be enrolled in this study. 12
      Patients will be treated with Malathion Gel, 0.5% and other 12 Patients will be treated with
      Ovide Lotion 0.5%. The study will be single centre and conducted only in India. The primary
      objective of this study is to compare the systemic exposure of Malathion 0.5% Gel
      manufactured by Taro Pharmaceuticals USA, Inc. to that of the OVIDE Lotion 0.5%, currently
      marketed by Taro Pharmaceutical USA, Inc., in adult Patients with head lice. The secondary
      objective is to determine the link between the exposure and cholinesterase activity.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement of blood and urinary levels of malathion and metabolites</measure>
    <time_frame>48 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure cholinesterase levels and compare to malathion metabolite levels</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Pediculosis</condition>
  <arm_group>
    <arm_group_label>Malathion gel 0.05%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Malathion gel 0.5% topical treatment for head lice</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Malathion lotion 0.5%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Malathion lotion 0.5% treatment for head lice</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Malathion gel 0.5%</intervention_name>
    <description>Malathion gel 0.5% applied to the scalp for 30 minutes</description>
    <arm_group_label>Malathion gel 0.05%</arm_group_label>
    <other_name>MALG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Malathion lotion 0.5%</intervention_name>
    <description>Malathion lotion 0.5% applied to scalp for 12 hours</description>
    <arm_group_label>Malathion lotion 0.5%</arm_group_label>
    <other_name>OVIDE lotion</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or non-pregnant female

          -  Patients 18 years of age or older and healthy presenting with Pediculosis capitis

          -  The Patient must be willing to consent to the Patient's treatment with Malathion Gel
             0.5% or Ovide Lotion 0.5% and for blood drawings before and after medication
             administration.

        Exclusion Criteria:

          -  Individuals with history of irritation or sensitivity to pediculicides or hair care
             products

          -  Individuals with any visible skin/scalp condition at the treatment site which, in the
             opinion of the investigative personnel, or Sponsor, will interfere with the
             evaluation.

          -  Individuals previously treated with a pediculicide within 4 weeks of the study.

          -  Individuals who exhibit potential signs and symptoms of cholinesterase inhibition.

          -  Patients currently receiving sulfonamide antibiotics or ivermectin.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Rabale</city>
        <state>Navi Mumbai</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <reference>
    <citation>Meinking TL, Vicaria M, Eyerdam DH, Villar ME, Reyna S, Suarez G. A randomized, investigator-blinded, time-ranging study of the comparative efficacy of 0.5% malathion gel versus Ovide Lotion (0.5% malathion) or Nix Cr√®me Rinse (1% permethrin) used as labeled, for the treatment of head lice. Pediatr Dermatol. 2007 Jul-Aug;24(4):405-11.</citation>
    <PMID>17845167</PMID>
  </reference>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 23, 2009</study_first_submitted>
  <study_first_submitted_qc>June 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2009</study_first_posted>
  <last_update_submitted>December 21, 2013</last_update_submitted>
  <last_update_submitted_qc>December 21, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Head Lice</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lice Infestations</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malathion</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

